Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update
Last Updated: Wednesday, February 16, 2022
This update to the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline addresses which patients should be treated with bone-modifying agents; recommended bisphosphonates for adjuvant therapy and optimal doses, durations, and routes; and the role of denosumab as adjuvant therapy, among other important clinical questions.
Advertisement
News & Literature Highlights